eoe sub articles

EoE Sub Articles

All procedures involving animal models have been reviewed by the local institutional animal care committee and the JoVE veterinary review board.
1. Isolation and Differentiation of Bone Marrow-derived Macrophages (BMMs)
<ol>
	<li>Day 0:&#160;Sacrifice 4 - 6-week-old female&#160;C57BL/6&#160;or&#160;BALB/c&#160;mouse in a CO2&#160;chamber and confirm death via cervical dislocation. Ensure sterilization of scissors and forceps by keeping them soaked in 70% ethanol. Spray gloves with 70% ethanol to allow sterile handling throughout the bone marrow cell isolation process.</li>
	<li>Secure the sacrificed mouse to the dissection board by pinning its forelimbs and disinfecting it by spraying copiously with 70% ethanol.</li>
	<li>Make a small incision (about 1 cm) with scissors near the hip joint. Carefully insert scissors under the skin to separate the underlying muscle and cut the skin around the hip joint.&#160;&#160;&#160;&#160; 
	NOTE: The dissection board may be rotated to allow improved access to the hip joint.</li>
	<li>Carefully degloved skin from the leg by pulling towards the ankle and removing it. Cut the foot off at the ankle, being very careful to cut at or below the ankle joint to leave the tibia fully intact.&#160;&#160;&#160;&#160;&#160;&#160;&#160; 
	NOTE: The fibula at this stage is loosely attached and can be easily separated with the forceps.</li>
	<li>Manually locate the hip joint by manipulating the femur to identify the point of rotation. Carefully use scissors to sever the leg above the hip joint to leave the proximal head of the femur intact.</li>
	<li>Remove as much muscle and connective tissue as possible from the leg with scissors. Remove any remaining skin from the ankle and any excess bone material above the hip joint.</li>
	<li>Place the cleaned leg bones in sterile Roswell Park Memorial Institute RPMI supplemented with penicillin/streptomycin (1% final concentration) in a Petri dish on ice.</li>
	<li>Repeat steps 1.4 through 1.6 to isolate the tibia and femur from the other hind leg.</li>
	<li>Remove any remaining muscle and connective tissue from the bones soaking in RPMI using sterilized forceps and sterile #10 blade.</li>
	<li>Place bones on the Petri dish lid. Cut the tibia carefully with the blade immediately above the ankle joint to access the marrow. Remove the tibia from the rest of the leg by cutting immediately below the knee joint.</li>
	<li>Draw 10 mL sterile RPMI supplemented with penicillin/streptomycin (1% final concentration) into a 10-mL syringe and attach a 25G needle.</li>
	<li>Hold the tibia firmly with forceps, vertically over a 50-mL conical tube on ice. Use the syringe to gently inject approximately 5 mL RPMI into the end of the bone to flush the bone marrow out of the other end into the conical tube. Flush the bone marrow with a total of 10 mL RPMI until the bone turns white.&#160;&#160;&#160;&#160; 
	NOTE: After thorough flushing, the bone should turn white. If not, continue flushing to remove marrow. The distal end of the tibia may need to be trimmed back with the blade if it is too narrow to insert the needle.</li>
	<li>Cut the femur immediately above the knee joint and immediately below the hip joint to expose both ends of the bone to access the marrow. Flush bone marrow from the femur with a total of 10 mL RPMI in the same fashion as the tibia.</li>
	<li>Repeat cleaning and flushing steps 1.6 through 1.13 with the remaining bones and collect the bone marrow flushed cells in a single 50 mL conical tube 
	NOTE: If a bone breaks at any point during dissection before bone flushing, do not use the marrow from this bone.</li>
	<li>Centrifuge the conical tube used to collect bone marrow flushed from all four bones for 10 min at 4 &#176;C at 300 x g.</li>
	<li>Place 60 mL of sterile BMM medium (RPMI with a final concentration of 20% fetal bovine serum, FBS, 1% penicillin/streptomycin, 1.2 mM Na-pyruvate, 25 &#181;g/mL human Macrophage Colony-Stimulating Factor (M-CSF) into a 175 cm2&#160;cell culture flask with filter cap.</li>
	<li>Discard the supernatant following centrifugation and resuspend the cell pellet by gentle up and down pipetting using 5 mL of BMM medium from the flask.</li>
	<li>Transfer cell suspension to the culture flask and rinse the conical tube twice with BMM medium from the culture flask to ensure maximal cell recovery. Ensure cell suspension is thoroughly mixed into a medium, and distribute 30 mL from the initial 175 cm2&#160;cell culture flask to a second 175 cm2&#160;cell culture flask with a filter cap.</li>
	<li>Incubate both flasks containing 30 mL cell suspension each overnight at 37 &#176;C, 5% carbon dioxide (CO2) to allow separation of any contaminating fibroblasts, resident macrophages, and other adherent cells.</li>
	<li>DAY 1:&#160;Transfer the supernatant containing undifferentiated bone marrow cells from flasks to 100 mm x 15 mm non-TC-treated polystyrene Petri dishes at approximately 10 mL/dish and incubate at 37 &#176;C, 5% CO2.&#160;Discard the flasks.</li>
	<li>DAY 3 or 4:&#160;Add an additional 5 mL BMM medium (pre-warmed to 37 &#176;C) to each Petri dish and continue incubation at 37 &#176;C, 5% CO2.</li>
</ol>
2. Plating BMMs on Coverslips for Infection (DAY 7 or 8)
<ol>
	<li>Prepare 6-well tissue culture plates by placing four (4) sterile 12 mm glass coverslips (autoclaved and stored in a closed glass container) in the bottom of each empty well.&#160;&#160;&#160;&#160; 
	NOTE: Pick each sterile 12 mm coverslip up with an aspirating tip fitted to a vacuum line. Place coverslips into the wells without overlap, releasing them at the desired position by pinching the tube to interrupt the vacuum.</li>
	<li>Aspirate media (and any non-adherent cells) from Petri dishes coated with adherent bone marrow-derived macrophages and gently rinse adherent cells 2x with sterile Dulbecco&#39;s Phosphate buffered saline without calcium and magnesium chloride (PBS -/-) pre-warmed to 37 &#176;C.</li>
	<li>Add dropwise, 5 mL sterile 1x PBS -/- with a final concentration of 1 mM ethylenediaminetetraacetic acid (EDTA) to each Petri dish and incubate for 5 min at 37 &#176;C to detach adherent BMMs. Verify that the cells are detached using a microscope.</li>
	<li>Collect all detached cells suspended in 1x PBS -/- supplemented with 1 mM EDTA in a 50 mL conical tube. Rinse each dish 2x with 5 mL PBS -/- and add to the cell suspension pool.&#160;&#160;&#160; 
	NOTE: Cell suspension may be diluted with additional PBS -/- to protect macrophages from EDTA toxicity during the collection process.</li>
	<li>Centrifuge at 300 x g for 10 min at 4 &#176;C. Discard supernatant and resuspend macrophages in 5 - 10 mL BMM medium by pipetting. Place resuspended cells on ice to prevent attachment to tubes and clumping.</li>
	<li>Count viable cells using Trypan blue exclusion in the hemocytometer. 
	NOTE: To count BMM cells resuspended in 5 mL medium, a dilution mix of 25 &#181;L cell suspension in 445 &#181;L PBS -/- and 30 &#181;L 0.4% Trypan blue solution typically allows easy quantification in a hemocytometer (taking into account a 20x dilution factor for the final calculation). Count only cells that did not get stained with Trypan blue (viable cells). The volume of cell suspension may be altered if this mixture is too concentrated or diluted. In general, the yield of BMM per preparation varies between 2 x 107&#160;and 5 x 107&#160;cells from a single mouse.</li>
	<li>Prepare the cell suspension in BMM medium at the desired plating concentration (5 x 105/mL) and disperse suspension to 6 well plates in 2 mL medium per well so that each well receives 1 x 106&#160;macrophages.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 
	NOTE: This is a critical step that ensures every well gets an adequate number of macrophages to cover the coverslips uniformly. Check that the coverslips in wells are not overlapping or floating in the medium. If so, gently adjust with a sterile pipette tip.</li>
	<li>Incubate overnight at 37 &#176;C, 5% CO2.</li>
</ol>
3. Purification of Infective Forms of&#160;Leishmania amazonensis
NOTE: Prepare&#160;Leishmania&#160;for infections- purify metacyclic promastigotes from stationary promastigote cultures, or differentiate promastigotes in culture into amastigote form using standard&#160;L. amazonensis&#160;axenic differentiation protocol.
<ol>
	<li>Purification of&#160;Leishmania&#160;metacyclic promastigotes using density gradient media(Materials)
	<ol>
		<li>Prepare 40% stock solution of density gradient media in sterile, endotoxin-free water.</li>
		<li>Dilute density gradient solution in 10x M199 medium (without serum) to prepare 10% concentration in the M199 medium.</li>
		<li>Filter all solutions through a 0.22 &#181;m filter.&#160;&#160;&#160;&#160;&#160;&#160;&#160; 
		NOTE: Stock solutions can be stored at 4&#160;oC in darkness for no longer than 1 month.</li>
		<li>Add 2 mL of 40% density gradient media solution in the bottom of a 15-mL conical centrifuge tube.</li>
		<li>Layer 2 mL of 10% density gradient media solution in M199 on top of the 40% density gradient media layer carefully, using a Pasteur pipette to avoid any mixing between the two layers.</li>
		<li>Collect 1 x 109&#160;parasites from stationary-phase culture by centrifugation at 1,900 x g for 10 min.</li>
		<li>Resuspend cells in 6 mL Dulbecco&#39;s Modified Essential Medium (DMEM).</li>
		<li>Layer 2 mL of the cell suspension directly on top of the 10% density gradient media layer, gently, using a Pasteur pipette to avoid mixing between layers.</li>
		<li>Centrifuge the gradient for 10 min at 1,300 x g at room temperature. 
		NOTE: Due to differences in physical properties between&#160;Leishmania&#160;species, centrifugation conditions for each might have to be slightly adjusted to ensure maximum yield.</li>
		<li>Collect parasites (enriched in metacyclic promastigote form) from the band formed at the upper 10% density gradient media boundary (interface between the 0% and 10% density gradient media layers).</li>
		<li>Dilute parasites with one volume of DMEM and collect by centrifugation (1,900 x g for 10 min at room temperature).</li>
		<li>Resuspend in 500 &#181;L DMEM medium and count in a hemocytometer to quantify yield.</li>
	</ol>
	</li>
	<li>Generation of&#160;L. amazonensis&#160;amastigotes under axenic culture conditions (low pH / elevated temperature)
	<ol>
		<li>Mix 5 mL of log-phase promastigote culture (pH 7.4 at 26&#160;oC) with an equal volume of amastigote medium (pH 4.5), using 25 cm2&#160;flasks (total 10 mL medium), and incubate at 26 &#176;C overnight.</li>
		<li>Shift the flask from 26 &#176;C to 32 &#176;C.</li>
		<li>After 3 or 4 days, split culture 1:5 in amastigote media at 32 &#176;C.</li>
		<li>Check the parasites in the next 3 - 4 days (maximum 7 days) to see if they are ready for use in infections.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 
		NOTE: Healthy axenic amastigotes should have an oval shape, without visible flagella. Partially differentiated amastigotes have a large oval shape with short flagella. The culture should not have a lot of clumps - many clumps are an indication of non-growing, dying parasites. The amastigote culture can be split 1:5 and maintained for a maximum of 3 weeks.</li>
	</ol>
	</li>
</ol>
4. Infection with&#160;L. amazonensis
<ol>
	<li>Dilute parasite suspensions according to desired multiplicity of infection (MOI) (usually 3-5 metacyclic promastigotes per macrophage [MOI of 1:3 or 1:5] and 1 amastigote per macrophage [MOI 1:1]). Add&#160;Leishmania&#160;in PBS -/- in a volume of 50 - 100 &#181;L to each well already containing 2 mL medium.</li>
	<li>Incubate BMMs for 1 h with amastigotes and 3 h with metacyclic promastigotes at 34&#160;oC for infection.&#160;&#160;&#160;&#160;&#160;&#160; 
	NOTE: Optimal infection temperature may vary by species.</li>
	<li>Following incubation, thoroughly wash away free parasites in each well 3x with 2 mL PBS -/- pre-warmed to 37 &#176;C.&#160;&#160;&#160;&#160;&#160;&#160; 
	NOTE: Disperse PBS gently to ensure that coverslips do not float over each other. Gently swirl the plate and then aspirate out the liquid. Use a separate aspirating tip if using multiple strains of parasites to avoid cross-contamination.</li>
	<li>Fix 1 h or 3 h time-point samples by incubating each well with 1.5 - 2 mL of 2% PFA in PBS -/- for 10 min. Wash 3x with PBS -/-. Do not aspirate last wash and refrigerate plates containing coverslips in PBS until staining.</li>
	<li>Add 2 mL fresh BMM medium to each well on plates for further time points and incubate at 34 &#176;C.</li>
	<li>Fix remaining time points as desired as described in step 4.3, and refrigerate plates until staining.</li>
</ol>
5. 4&#8242;,6-diamidino-2-phenylindole (DAPI) Staining and Coverslip Mounting
<ol>
	<li>Aspirate PBS from wells containing coverslips and add 1.5 mL PBS -/- with 0.1% non-ionic detergent. Incubate for 10 min at room temperature, followed by 3x wash with 2 mL PBS -/-.</li>
	<li>Add 1 mL PBS -/- with 2 &#181;g/mL DAPI (diluted from 5 mg/mL stock solution in water) to wells containing coverslips and incubate for another 1 h at room temperature. 
	NOTE: The incubation time with DAPI is critical for proper visualization of intracellular&#160;Leishmania&#160;parasites. Macrophage nuclei stain rapidly, due to their larger size and deoxyribonucleic acid (DNA) content but staining of nuclei of the intracellular parasites is slower. Thus, extending incubation time beyond what is required to visualize the BMM nuclei is necessary to allow DAPI to permeate through the parasite plasma membrane and the parasite nuclear membrane. With proper DAPI stain, the mitochondrial kinetoplast DNA near the flagellar pocket of the parasite can also be visualized, in addition to the nuclear DNA.</li>
	<li>Wash each well containing coverslips 3x with 2 mL PBS -/- and then lift and flip coverslips with forceps to place the cell side down and mount on glass microscope slides with a commercially available antifade mounting reagent.&#160;&#160;&#160;&#160;&#160;&#160;&#160; 
	NOTE: Coverslips are extremely fragile and need cautious handling. Avoid putting pressure on them, especially against the sidewall of the wells when lifting. Adding a few drops of PBS -/- reduces the surface tension between the coverslip and the well and facilitates the lifting process. A fine gauge needle may be used to assist in prying the coverslips from the bottom of the well. After placing a coverslip on the slide, gently press down with forceps to push out any air bubbles in the mounting media. If a coverslip is broken or has possibly flipped during the lifting process, do not remount; simply use the spare fourth coverslip.</li>
	<li>Refrigerate slides until quantification.</li>
</ol>
6. Infection Quantification
<ol>
	<li>Examine DAPI-stained slides under a fluorescence microscope by focusing on macrophages using a 100X&#160;objective lens with immersion oil (excitation at 358 nm; optimal emission at 461 nm). 
	Ensure that the focus is on the layer of macrophages between the glass slide and coverslip.</li>
	<li>Quantify the number of macrophages (large nuclei stained with DAPI) and the number of smaller amastigote nuclei clustered around each macrophage nucleus (see&#160;Figure 1A, DAPI) for each field of vision, using a manual counter. 
	NOTE: Amastigote nuclei may not all be visible in one plane of focus due to their small size. Count those that are visible when focused on macrophage nuclei, and then use fine focus to check for parasite nuclei in planes above and below the macrophage nuclei.</li>
	<li>Move to another field of vision to repeat quantification. Use a separate counter key to track the number of fields counted. Move through visual fields in parallel rows across each coverslip, to prevent counting overlap.</li>
	<li>Quantify a minimum of 200 macrophages per coverslip. Quantify each time-point of infection in triplicate (3 coverslips). Count the fourth coverslip if one of the previous ones is not suitable for counting due to coverslip overlap, poor mounting, glass breakage,&#160;etc. 
	NOTE: If 200 macrophages cannot be counted on any one coverslip, count the spare fourth.</li>
	<li>Calculate infection rates as amastigotes/macrophage or amastigotes/100 macrophages and determine the percent infected macrophages from the raw quantification data.</li>
</ol>

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>6 well cell culture plate</td>
			<td>Cellstar</td>
			<td>657160</td>
			<td></td>
		</tr>
		<tr>
			<td>Adenine</td>
			<td>Acros Organics</td>
			<td>AC147440250</td>
			<td></td>
		</tr>
		<tr>
			<td>Aerosol Barrier Pipet Tips (100-1000 &#956;L)</td>
			<td>Fisherbrand</td>
			<td>02-707-404</td>
			<td></td>
		</tr>
		<tr>
			<td>Aerosol Barrier Pipet Tips (20-200 &#956;L)</td>
			<td>Fisherbrand</td>
			<td>02-707-430</td>
			<td></td>
		</tr>
		<tr>
			<td>Aerosol Barrier Pipet Tips (2-20 &#956;L)</td>
			<td>Fisherbrand</td>
			<td>02-707-432</td>
			<td></td>
		</tr>
		<tr>
			<td>Bard-Parker Rib-Back Carbon Steel Surgical Blade #10</td>
			<td>Aspen Surgical</td>
			<td>371110</td>
			<td></td>
		</tr>
		<tr>
			<td>BD Luer-Lok Tip 10 mL Syringe</td>
			<td>Becton Dickinson (BD)</td>
			<td>309604</td>
			<td></td>
		</tr>
		<tr>
			<td>BD Precisionglide Needle, 25G&#160;</td>
			<td>Becton Dickinson (BD)</td>
			<td>305124</td>
			<td></td>
		</tr>
		<tr>
			<td>Cell Culture Dish 35 mm x 10 mm</td>
			<td>Cellstar</td>
			<td>627 160</td>
			<td></td>
		</tr>
		<tr>
			<td>Cell Culture Flask</td>
			<td>Cellstar</td>
			<td>660175</td>
			<td></td>
		</tr>
		<tr>
			<td>Cover Glasses: 12 mm circles</td>
			<td>Fisherbrand</td>
			<td>12-545-80</td>
			<td></td>
		</tr>
		<tr>
			<td>DAPI (4&#39;,6-Diamidino-2-Phenylindole, Dihydrochloride)</td>
			<td>Invitrogen</td>
			<td>D1306</td>
			<td></td>
		</tr>
		<tr>
			<td>D-Biotin</td>
			<td>J.T. Baker</td>
			<td>C272-00</td>
			<td></td>
		</tr>
		<tr>
			<td>EDTA</td>
			<td>Sigma Aldrich</td>
			<td>EDS</td>
			<td></td>
		</tr>
		<tr>
			<td>Ethyl alcohol 200 proof</td>
			<td>Pharmco-AAPER</td>
			<td>111000200</td>
			<td></td>
		</tr>
		<tr>
			<td>Falcon 100 mm x 15 mm non-TC-treated polystyrene Petri dish</td>
			<td>Corning</td>
			<td>351029</td>
			<td></td>
		</tr>
		<tr>
			<td>Fetal Bovine Serum</td>
			<td>Seradigm</td>
			<td>1500-500</td>
			<td></td>
		</tr>
		<tr>
			<td>Ficoll400</td>
			<td>Sigma Aldrich</td>
			<td>F8016</td>
			<td></td>
		</tr>
		<tr>
			<td>Fluorescence Microscope</td>
			<td>Nikon</td>
			<td>E200</td>
			<td></td>
		</tr>
		<tr>
			<td>Goat anti-mouse IgG Texas red</td>
			<td>Invitrogen</td>
			<td>T-862</td>
			<td></td>
		</tr>
		<tr>
			<td>Goat anti-rabbit IgG AlexaFluor488</td>
			<td>Invitrogen</td>
			<td>A-11034</td>
			<td></td>
		</tr>
		<tr>
			<td>Hemin</td>
			<td>Tokyo Chemical Industry Co. LTD</td>
			<td>H0008</td>
			<td></td>
		</tr>
		<tr>
			<td>HEPES (1M)</td>
			<td>Gibco</td>
			<td>15630-080</td>
			<td></td>
		</tr>
		<tr>
			<td>Isoton II Diluent</td>
			<td>Beckman Coulter</td>
			<td>8546719</td>
			<td></td>
		</tr>
		<tr>
			<td>L-Glutamine</td>
			<td>Gemini</td>
			<td>400-106</td>
			<td></td>
		</tr>
		<tr>
			<td>Medium 199 (10X)</td>
			<td>Gibco</td>
			<td>11825-015</td>
			<td></td>
		</tr>
		<tr>
			<td>Na pyruvate (100 mM)</td>
			<td>Gibco</td>
			<td>11360-070</td>
			<td></td>
		</tr>
		<tr>
			<td>Paraformaldehyde</td>
			<td>Alfa Aesar</td>
			<td>43368</td>
			<td></td>
		</tr>
		<tr>
			<td>Penicillin/Streptomycin</td>
			<td>Gemini</td>
			<td>400-109</td>
			<td></td>
		</tr>
		<tr>
			<td>Phosphate Buffered Saline (-/-)</td>
			<td>ThermoFisher</td>
			<td>14200166</td>
			<td></td>
		</tr>
		<tr>
			<td>Polypropyline conical Centrifuge Tubes 15 mL</td>
			<td>Cellstar</td>
			<td>188 271</td>
			<td></td>
		</tr>
		<tr>
			<td>Polypropyline conical Centrifuge Tubes 50 mL</td>
			<td>Cellstar</td>
			<td>227 261</td>
			<td></td>
		</tr>
		<tr>
			<td>ProLong Gold antifade reagent</td>
			<td>ThermoFisher</td>
			<td>P36930</td>
			<td></td>
		</tr>
		<tr>
			<td>Rat anti-mouse Lamp-1 antibody</td>
			<td>Developmental Studies Hybridoma Bank</td>
			<td>1D4B</td>
			<td></td>
		</tr>
		<tr>
			<td>Recombinant Human M-CSF</td>
			<td>PeproTech</td>
			<td>300-25</td>
			<td></td>
		</tr>
		<tr>
			<td>Reichert Bright-Line&#160; Hemocytometer&#160;</td>
			<td>Hausser Scientific</td>
			<td>1492</td>
			<td></td>
		</tr>
		<tr>
			<td>RPMI Medium 1640 (1X)</td>
			<td>Gibco</td>
			<td>11875-093</td>
			<td></td>
		</tr>
		<tr>
			<td>Triton X-100 Surfactant</td>
			<td>Millipore Sigma</td>
			<td>TX1568-1</td>
			<td></td>
		</tr>
		<tr>
			<td>Trypan Blue</td>
			<td>Sigma Aldrich</td>
			<td>T8154</td>
			<td></td>
		</tr>
		<tr>
			<td>Delicate Scissors, 4 1/2&#34;</td>
			<td>VWR</td>
			<td>82027-582</td>
			<td></td>
		</tr>
		<tr>
			<td>Dissecting Forceps, Fine Tip</td>
			<td>VWR</td>
			<td>82027-386</td>
			<td></td>
		</tr>
		<tr>
			<td>Microscope Slides</td>
			<td>VWR</td>
			<td>16004-368</td>
			<td></td>
		</tr>
		<tr>
			<td>Z1 Coulter Particle Counter, Dual Threshold</td>
			<td>Beckman Coulter</td>
			<td>6605699</td>
			<td></td>
		</tr>
	</tbody>
</table>

assessment of leishmania virulence within cultured macrophages

Source: Sarkar, A. et al., <a href="https://app.jove.com/v/57486">Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of&#160;Leishmania&#160;Parasites.</a>&#160;J. Vis. Exp.&#160;(2018)
This video investigates Leishmania&#39;s virulence by treating macrophages with metacyclic promastigotes, resulting in the formation of intracellular amastigotes. The confirmation of Leishmania&#39;s virulence is achieved through nucleic acid fluorescent dye staining. This insight can contribute to the development of new therapies for leishmaniasis.

<img alt="Figure 1" src="/files/ftp_upload/21792/21792_Figure1.jpg" /> 
Figure 1: A representative illustration of BMM infection with virulent axenic amastigotes (A) and non-virulent log-phase promastigotes (B) of&#160;L. amazonensis.&#160;Immunofluorescence images of macrophages isolated from&#160;BALB/c&#160;mice, 1 h and 48 h following infection. Infected macrophages were processed for immunofluorescence as described in the protocol. PV membranes...

Assessment of Leishmania Virulence within Cultured Macrophages

All procedures involving animal models have been reviewed by the local institutional animal care committee and the JoVE veterinary review board.
1. ...

Begin with a multi-well plate containing bone marrow-derived macrophages on coverslips.
Treat the macrophages with Leishmania promastigotes &#8212; the parasite&#39;s infectious stage.
During incubation, the parasites interact with macrophages, facilitating the assembly of F-actin around the interaction site.
Macrophages engulf the parasites in F-actin-surrounded phagosomes, forming parasitophorous vacuoles or PVs &#8212; a replicative niche.
Within PVs, parasites release survival factors, increasing F-actin accumulation around the vacuoles and inhibiting their fusion with lysosomes.
Additionally, parasites upregulate the production of hepcidin &#8212; a macrophage peptide hormone, inhibiting iron release and elevating intracellular iron levels.
The iron influx into vacuoles promotes promastigote differentiation into pathogenic amastigotes and facilitates their multiplication, enhancing virulence.
Post-incubation, wash to remove free parasites, then, fix and permeabilize the infected macrophages.
Introduce a nucleic acid fluorescent dye to stain the nuclei of infected macrophages and amastigotes.
Under a fluorescence microscope, small nuclei clustered around the macrophage&#39;s large nucleus confirm the presence of intracellular parasites, demonstrating Leishmania&#39;s virulence.

assessment-of-leishmania-virulence-within-cultured-macrophages

Research

JoVE Encyclopedia of Experiments

Immunology

Immunodiagnostics

Imaging and Visualization Techniques

147 조회수. 출처: Sarkar, A. et al., 대식세포 내 세포 내 성장의 정량화는 리슈마니아 기생충의 독성을 평가하기 위한 빠르고 신뢰할 수 있는 방법입니다.J. Vis. 특급(2018년) 이 비디오는 대식세포를 메타고리 전구세포로 처리하여 세포 내 변형체를 형성함으로써 리슈마니아의 독성을 조사합니다. 리슈마니아의 독성은 핵산 형광 염료 염색을 통해 확인됩니다. 이러한 통찰력은 리슈마니아증?...

비디오: 배양된 대식세포 내 Leishmania Virulence 평가 - 개념

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Leishmania spp. are protozoan parasites that cause leishmaniases, diseases that present a wide spectrum of clinical manifestations from cutaneous to visceral lesions. Currently, 12 million people are estimated to be infected with Leishmania worldwide and over 1 billion people live at the risk of infection. Leishmania amazonensis is endemic in Central and South America and usually leads to the cutaneous form of the disease, which can be directly visualized in an animal model. Therefore, L. amazonensis strains are good models for cutaneous leishmaniasis studies because they are also easily cultivated in vitro. C57BL/6 mice mimic the L. amazonensis-driven disease progression observed in humans and are considered one of the best mice strains model for cutaneous leishmaniasis. In the vertebrate host, these parasites inhabit macrophages despite the defense mechanisms of these cells. Several studies use in vitro macrophage infection assays to evaluate the parasite infectivity under different conditions. However, the in vitro approach is limited to an isolated cell system that disregards the organism&#39;s response. Here, we compile an in vivo murine infection method that provides a systemic physiological overview of the host-parasite interaction. The detailed protocol for the in vivo infection of C57BL/6 mice with L. amazonensis comprises parasite differentiation into infective amastigotes, mice footpad cutaneous inoculation, lesion development, and parasite load determination. We propose this well-established method as the most adequate method for physiological studies of the host immune and metabolic responses to cutaneous leishmaniasis.

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Here, we present a compiled protocol to evaluate the cutaneous infection of mice with Leishmania amazonensis. This is a reliable method for studying parasite virulence, allowing a systemic view of the vertebrate host response to the infection.

리슈마니아 아마존과 생체 감염에서 마우스에서 기생충 독성을 평가하기 위해

Leishmania spp. are protozoan parasites that cause leishmaniases, diseases that present a wide spectrum of clinical manifestations from cutaneous to ...

연구

JoVE Journal

면역학 및 감염병학

Investigating the Phagocytosis of Leishmania using Confocal Microscopy

Phagocytosis is an orchestrated process that involves distinct steps: recognition, binding, and internalization. Professional phagocytes take up Leishmania parasites by phagocytosis, consisting of recognizing ligands on parasite surfaces by multiple host cell receptors. Binding of Leishmania to macrophage membranes occurs through complement receptor type 1 (CR1) and complement receptor type 3 (CR3) and Pattern Recognition Receptors. Lipophosphoglycan (LPG) and 63 kDa glycoprotein (gp63) are the main ligands involved in macrophage-Leishmania interactions. Following the initial recognition of parasite ligands by host cell receptors, parasites become internalized, survive, and multiply within parasitophorous vacuoles. The maturation process of Leishmania-induced vacuoles involves the acquisition of molecules from intracellular vesicles, including monomeric G protein Rab 5 and Rab 7, lysosomal associated membrane protein 1 (LAMP-1), lysosomal associated membrane protein 2 (LAMP-2), and microtubule-associated protein 1A/1B-light chain 3 (LC3).
Here, we describe methods to evaluate the early events occurring during Leishmania interaction with the host cells using confocal microscopy, including (i) binding (ii) internalization, and (iii) phagosome maturation. By adding to the body of knowledge surrounding these determinants of infection outcome, we hope to improve the understanding of the pathogenesis of Leishmania infection and support the eventual search for novel chemotherapeutic targets.

Investigating the Phagocytosis of Leishmania using Confocal Microscopy

The mechanism associated with phagocytosis in Leishmania infection remains poorly understood. Here, we describe methods to evaluate the early events occurring during Leishmania interaction with the host cells.

공초점 현미경을 사용하여 리슈마니아 의 식균작용 조사

Phagocytosis is an orchestrated process that involves distinct steps: recognition, binding, and internalization. Professional phagocytes take up ...

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Understanding the function and mechanism of pore-forming toxins (PFTs) is challenging because cells resist the membrane damage caused by PFTs. While biophysical approaches help understand pore formation, they often rely on reductionist approaches lacking the full complement of membrane lipids and proteins. Cultured human cells provide an alternative system, but their complexity and redundancies in repair mechanisms make identifying specific mechanisms difficult. In contrast, the human protozoan pathogen responsible for cutaneous leishmaniasis, Leishmania major,&#160;offers an optimal balance between complexity and physiologic relevance. L. major is genetically tractable and can be cultured to high density in vitro, and any impact of perturbations on infection can be measured in established murine models. In addition, L. major synthesizes lipids distinct from their mammalian counterparts, which could alter membrane dynamics. These alterations in membrane dynamics can be probed with PFTs from the best-characterized toxin family, cholesterol-dependent cytolysins (CDCs). CDCs bind to ergosterol in the Leishmania membrane and can kill L. major promastigotes, indicating that L. major is a suitable model system for determining the cellular and molecular mechanisms of PFT function. This work describes methods for testing PFT function in L. major promastigotes, including parasite culture, genetic tools for assessing lipid susceptibility, membrane binding assays, and cell death assays. These assays will enable the rapid use of L. major as a powerful model system for understanding PFT function across a range of evolutionarily diverse organisms and commonalities in lipid organization.

Deciphering the Molecular Mechanism and Function of Pore-Forming Toxins Using Leishmania major

Presented here is a protocol using Leishmania major promastigotes to determine the binding, cytotoxicity, and signaling induced by pore-forming toxins. A proof-of-concept with streptolysin O is provided. Other toxins can also be used to leverage the genetic mutants available in L. major to define new mechanisms of toxin resistance.

리슈만편모충 전공을 이용한 기공 형성 독소의 분자 메커니즘과 기능 해독

Understanding the function and mechanism of pore-forming toxins (PFTs) is challenging because cells resist the membrane damage caused by PFTs. While ...

Assessment of Leishmania Virulence within Cultured Macrophages

내레이션 대본

Assessment of Leishmania Virulence within Cultured Macrophages